Understanding clopidogrel efficacy in the presence of cytochrome P450 polymorphism
- PMID: 16754901
- PMCID: PMC1471829
- DOI: 10.1503/cmaj.060502
Understanding clopidogrel efficacy in the presence of cytochrome P450 polymorphism
Comment on
-
Increased risk of atherothrombotic events associated with cytochrome P450 3A5 polymorphism in patients taking clopidogrel.CMAJ. 2006 Jun 6;174(12):1715-22. doi: 10.1503/cmaj.060664. CMAJ. 2006. PMID: 16754899 Free PMC article. Clinical Trial.
References
-
- Savi P, Herbert JM, Pflieger AM, et al. Importance of hepatic metabolism in the antiaggregating activity of the thienopyridine clopidogrel. Biochem Pharmacol 1992;44:527-32. - PubMed
-
- Herbert JM, Savi P, Maffrand JP. Biochemical and pharmacological properties of clopidogrel: a new ADP receptor antagonist. Eur Heart J 1999;(Suppl 1):A31-40.
-
- Clarke TA, Waskell LA. The metabolism of clopidogrel is catalyzed by human cytochrome P450 3A and is inhibited by atorvastatin. Drug Metab Dispos 2003;31:53-9. - PubMed
-
- Lau WC, Waskell LA, Watkins PB, et al. Atorvastatin reduces the ability of clopidogrel to inhibit platelet aggregation: a new drug–drug interaction. Circulation 2003;107:32-7. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical